Bortezomib in multiple myeloma: systematic review and clinical considerations. - Wikidata - wikimedia - TriplyDB

Bortezomib in multiple myeloma: systematic review and clinical considerations.

Bortezomib in multiple myeloma: systematic review and clinical considerations.

http://www.wikidata.org/entity/Q33982728

about

Targeting the ubiquitin pathway for cancer treatment Desensitization: Overcoming the Immunologic Barriers to Transplantation Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.Misfolded proteins: from little villains to little helpers in the fight against cancer.Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Small molecule therapeutics targeting F-box proteins in cancer.Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma.Bortezomib-induced acute pancreatitis: Case report and review of the literature.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia.Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas.Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors--implications for dose-sparing combination therapies.Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.

P2860

Q26866185-8E5FC6EF-6499-4430-A686-8E2735D7DC17 Q30397952-FA77B736-CB95-4C60-8867-2ACFEE9BB612 Q33430998-EDA50F59-5E9A-4E2C-8533-ABA80743E1E1 Q33828073-E9C17C71-DDD2-4372-BC41-826AD550C19F Q33887173-91187DEC-01B2-4494-9FEC-35B173488D93 Q34466592-EC5B876C-834E-4B6A-B490-4FCAE75A76CD Q34492636-B6DAF0CB-5D43-43C9-A693-FF3827387E4E Q35888867-844836C1-32EE-4764-8084-522E9699AC96 Q36356398-82698B4D-3665-4DAF-9465-A3A851D0249B Q36525841-9B7B3733-52F5-485B-A569-7B611C891324 Q36600976-2A1AF14F-623B-4D0B-98BD-22292492BD56 Q37109858-51106192-1B44-4344-A3E1-F06AD7D1780A Q37425782-C917CEC8-6C32-4378-9E58-DD6D619F1B38 Q37738092-775D4D99-3572-46BE-8FCB-3FBFC67A71B5 Q38291446-19E256DF-A316-4E89-8226-49228EBD970E Q38445336-D374B8E6-7B21-44CA-A5B1-69C90B20D796 Q38776733-C6A5B1AD-1EEB-4D3A-9441-AF26C2A376C0 Q40918755-3E2ADF5E-B4E8-4138-8F8A-D47CDF507B02 Q47421833-2A7546FA-F833-4F90-9F9E-F2E3E3521D31 Q47616385-644A61C1-1611-4FF9-B2F4-DBFFB9EF669D Q48089641-468CA51B-8732-47D1-84DA-7154F4FD64CF Q52666760-873E35A7-CE36-46DF-9F2F-D1BA70E9B8CB Q52856824-FF78AB30-E919-4B4D-BD45-DD75F76EE09B Q52859066-1B02E295-0CC6-40DD-91E2-A5DF9B122460 Q53296169-2705EFA5-706B-4647-9D02-9ECD0B5E7FA2 Q55208548-84C12015-CEBA-4904-B00E-215442E216A7

P2860

Bortezomib in multiple myeloma: systematic review and clinical considerations.

http://www.wikidata.org/entity/Q33982728

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@ast

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@en

type

label

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@ast

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@en

prefLabel

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@ast

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@en

P1433

Q33982728-F34F5939-AF02-4CFA-BD4A-340EB0D1C24A

P1476

Q33982728-3D85A89E-E4EB-4EF6-9F4F-8A8C5B265FFD

P2093

Q33982728-04A9AE17-EAF7-443F-B2E8-BA5C4D4F9040

Q33982728-4619ECF1-7E06-4ACE-A197-8704160F3B51

Q33982728-D255D6E6-9BC4-4C7E-A5EF-55C60C8C36A3

Q33982728-E8B9316A-D326-44C2-AAFE-1FC6EA71816A

Q33982728-EF0315C4-F113-4DA5-9B18-C932BA76AD7B

Q33982728-F7545F32-F6B0-4FD3-837D-F4E4B02615C4

P2860

Q33982728-069FC379-5F65-47A7-B3F8-2B3D0D3535BF

Q33982728-09DC4416-3187-4E8C-9951-9ED1F01B552C

Q33982728-0AD683C1-E411-4F5F-982D-B8457A25AF1F

Q33982728-159F0AAF-705C-460E-A1E1-1E71A5ECD680

Q33982728-15A34C58-20EB-4454-9952-D6D198937316

Q33982728-1ED66602-9CF5-4468-823B-7D3193FCD461

Q33982728-2639C1EC-6D74-4875-A8C3-579E0DF84119

Q33982728-267C7E79-B0AD-48B4-A322-DC608FCD0503

Q33982728-376AABA1-3D8D-460B-8D5E-3AF07B0F2EC6

Q33982728-3B97D81C-EAEE-4AEF-877A-A82DCA22086A

P304

Q33982728-D267F7DA-7C96-416F-AD93-C17A9837377A

P31

Q33982728-D5FF6E91-3E0D-4BCA-B740-8C13B5F27913

P356

Q33982728-E6DCE0F2-CB0A-4208-B168-AC08462F7A8A

P433

Q33982728-24E91040-8826-4D56-8999-26EDC6588EC4

P478

Q33982728-2891C90A-0706-4F31-BE87-6B7146511463

P577

Q33982728-CD9A1E76-FD21-4DED-A9F7-0E96752FD4BF

P5875

Q33982728-8DE8A57E-DA02-4D75-B5DF-95F358CE417D

P698

Q33982728-6FED4D86-8F17-4C74-9F00-4AE5AC4FFA3E

P932

Q33982728-5D1092AA-47DC-44EE-A08D-188F4E423DD6

P356

P1433

Current Oncology

P1476

Bortezomib in multiple myeloma: systematic review and clinical considerations.

@en

P2093

A E Haynes

http://www.w3.org/2001/XMLSchema#string

D E Reece

http://www.w3.org/2001/XMLSchema#string

F G Baldassarre

http://www.w3.org/2001/XMLSchema#string

K Imrie

http://www.w3.org/2001/XMLSchema#string

M C Cheung

http://www.w3.org/2001/XMLSchema#string

T C Kouroukis

http://www.w3.org/2001/XMLSchema#string

P2860

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

P304

e573-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.21.1798

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264463020

http://www.w3.org/2001/XMLSchema#string

P698

25089109

http://www.w3.org/2001/XMLSchema#string

P932

4117625

http://www.w3.org/2001/XMLSchema#string